Cargando…
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
Antibodies targeting the PD-1/PD-L1 immune checkpoint achieved spectacular success in anticancer therapy in the recent years. In contrast, no small molecules with cellular activity have been reported so far. Here we provide evidence that small molecules are capable of alleviating the PD-1/PD-L1 immu...
Autores principales: | Skalniak, Lukasz, Zak, Krzysztof M., Guzik, Katarzyna, Magiera, Katarzyna, Musielak, Bogdan, Pachota, Magdalena, Szelazek, Bozena, Kocik, Justyna, Grudnik, Przemyslaw, Tomala, Marcin, Krzanik, Sylwia, Pyrc, Krzysztof, Dömling, Alexander, Dubin, Grzegorz, Holak, Tad A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641120/ https://www.ncbi.nlm.nih.gov/pubmed/29069777 http://dx.doi.org/10.18632/oncotarget.20050 |
Ejemplares similares
-
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
por: Zak, Krzysztof M., et al.
Publicado: (2016) -
Human and mouse PD-L1: similar molecular structure, but different druggability profiles
por: Magiera-Mularz, Katarzyna, et al.
Publicado: (2020) -
PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Surmiak, Ewa, et al.
Publicado: (2021) -
Di-bromo-Based
Small-Molecule Inhibitors of
the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020) -
CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
por: Musielak, Bogdan, et al.
Publicado: (2019)